

Margret Schottelius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3319154/publications.pdf>

Version: 2024-02-01

84
papers

6,139
citations

61857

43
h-index

69108

77
g-index

87
all docs

87
docs citations

87
times ranked

5189
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus. EJNMMI Research, 2022, 12, 2.	1.1	6
2	Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed. EJNMMI Research, 2022, 12, .	1.1	1
3	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 2021, 109, 969-989.	1.5	28
4	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	2.9	8
5	Abstract 1304: AbYlink™: A site-selective labeling method for preclinical imaging of therapeutic antibodies. , 2021, , .		0
6	The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 261-270.	0.4	2
7	In Vivo Targeting of CXCR4 "New Horizons. Cancers, 2021, 13, 5920.	1.7	23
8	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction. Journal of Nuclear Medicine, 2020, 61, 234-241.	2.8	42
9	Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. Journal of Nuclear Medicine, 2020, 61, 13-19.	2.8	62
10	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. Bioconjugate Chemistry, 2020, 31, 375-395.	1.8	38
11	A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics, 2020, 10, 8264-8280.	4.6	33
12	"Luke! Luke! Don't! It's a trap!" spotlight on bias in animal experiments in nuclear oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1024-1026.	3.3	6
13	From Theranostics to Immunotheranostics: the Concept. Nuclear Medicine and Molecular Imaging, 2020, 54, 81-85.	0.6	3
14	[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Research, 2020, 10, 45.	1.1	33
15	Click Chemistry in the Design and Production of Hybrid Tracers. ACS Omega, 2019, 4, 12438-12448.	1.6	10
16	Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo. EJNMMI Research, 2019, 9, 75.	1.1	13
17	PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Seminars in Nuclear Medicine, 2019, 49, 302-312.	2.5	120
18	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 76, 517-523.	0.9	81

#	ARTICLE	IF	CITATIONS
19	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 156-157.	2.8	7
20	New Developments in Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 167-171.	2.8	41
21	Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 71-78.	2.8	76
22	^{99m} Tc-based Prostate-specific Membrane Antigen- ⁶⁸ Zn-radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	0.9	195
23	Synthesis and preclinical evaluation of novel ¹⁸ F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with ¹⁸ F-DCFPyl and ¹⁸ F-PSMA-1007. <i>EJNMMI Research</i> , 2018, 8, 30.	1.1	33
24	CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1048-1061.	3.2	34
25	Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. <i>EJNMMI Research</i> , 2018, 8, 84.	1.1	23
26	Effect of Carbohydraton on the Theranostic Tracer PSMA I&T. <i>ACS Omega</i> , 2018, 3, 8278-8287.	1.6	9
27	CXCR4-directed theranostics in oncology and inflammation. <i>Annals of Nuclear Medicine</i> , 2018, 32, 503-511.	1.2	98
28	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , 2018, 8, 369-383.	4.6	68
29	Value of ¹¹¹ In- ⁶⁸ Zn-prostate-specific membrane antigen (⁶⁸ Zn-PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. <i>BJU International</i> , 2017, 120, 40-47.	1.3	88
30	[⁶⁴ Cu]NOTA-pentixaether enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 2.	1.8	10
31	²¹³ Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 67-73.	0.7	47
32	Production of clinical radiopharmaceuticals: general pharmaceutical and radioanalytical aspects. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 311, 1551-1557.	0.7	2
33	Chemokine receptor - Directed imaging and therapy. <i>Methods</i> , 2017, 130, 63-71.	1.9	45
34	Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer ⁶⁸ Zn-Ga-Pentixafor for PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 499-506.	2.8	94
35	Preclinical Evaluation and First Patient Application of ^{99m} Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	2.8	170
36	Twins in spirit part IV - [177Lu] high affinity DOTATATE. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, 1-8.	0.3	6

#	ARTICLE	IF	CITATIONS
37	[¹⁷⁷ Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. <i>Theranostics</i> , 2017, 7, 2350-2362.	4.6	84
38	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. <i>Theranostics</i> , 2017, 7, 1589-1597.	4.6	102
39	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. <i>Theranostics</i> , 2016, 6, 849-861.	4.6	102
40	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	0.9	19
41	Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo—A comparison to [68Ga]pentixafor. <i>EJNMMI Research</i> , 2016, 6, 70.	1.1	18
42	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.2	166
43	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 932-940.	1.7	50
44	Inpatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e397-e402.	0.7	45
45	The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. <i>EJNMMI Research</i> , 2016, 6, 36.	1.1	32
46	Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 131-133.	1.4	44
47	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷ Lu- and ⁹⁰ Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	2.8	201
48	¹⁷⁷ Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1006-1013.	2.8	432
49	First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. <i>Tomography</i> , 2016, 2, 85-93.	0.8	22
50	MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER. <i>Journal of Urology</i> , 2015, 193, .	0.2	1
51	<i>In vivo</i> molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	3.3	180
52	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. <i>Theranostics</i> , 2015, 5, 618-630.	4.6	162
53	Prostate-specific Membrane Antigen—radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. <i>European Urology</i> , 2015, 68, 530-534.	0.9	192
54	Twins in spirit - episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE. <i>EJNMMI Research</i> , 2015, 5, 22.	1.1	47

#	ARTICLE	IF	CITATIONS
55	[¹¹¹ In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJMNM Research, 2015, 5, 68.	1.1	88
56	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸ Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	2.8	108
57	⁶⁸ Ga- and ¹⁷⁷ Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	2.8	432
58	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	2.8	122
59	An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Letters, 2015, 56, 6602-6605.	0.7	10
60	Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJMNM Research, 2014, 4, 63.	1.1	137
61	Twins in spirit part II: DOTATATE and high-affinity DOTATATE – the clinical experience. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1158-1165.	3.3	20
62	Pharmacophoric Modifications Lead to Superpotent $\alpha_5\beta_3$ Integrin Ligands with Suppressed $\alpha_5\beta_1$ Activity. Journal of Medicinal Chemistry, 2014, 57, 3410-3417.	2.9	35
63	Twins in spirit: DOTATATE and high-affinity DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1789-1789.	3.3	9
64	Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with [^{99m} Tc(OH) ₂] ₃ (CO) ₃]. Bioconjugate Chemistry, 2013, 24, 26-35.	1.8	13
65	A Conformationally Frozen Peptoid Boosts CXCR4 Affinity and Anti-HIV Activity. Angewandte Chemie - International Edition, 2012, 51, 8110-8113.	7.2	45
66	PET of CXCR4 Expression by a ⁶⁸ Ga-Labeled Highly Specific Targeted Contrast Agent. Journal of Nuclear Medicine, 2011, 52, 1803-1810.	2.8	182
67	¹⁸ F-Fluoroglucoosylation of peptides, exemplified on cyclo(RGDfK). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1469-1474.	3.3	59
68	Molecular imaging targeting peptide receptors. Methods, 2009, 48, 161-177.	1.9	181
69	Ligands for Mapping $\alpha_v\beta_3$ -Integrin Expression in Vivo. Accounts of Chemical Research, 2009, 42, 969-980.	7.6	285
70	Development of Novel ⁶⁸ Ga- and ¹⁸ F-Labeled GnRH-I Analogues with High GnRHR-Targeting Efficiency. Bioconjugate Chemistry, 2008, 19, 1256-1268.	1.8	40
71	Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Engineering, Design and Selection, 2007, 20, 273-284.	1.0	104
72	Synthesis of Novel 1,4,7,10-Tetraazacyclodecane-1,4,7,10-Tetraacetic Acid (DOTA) Derivatives for Chemoselective Attachment to Unprotected Polyfunctionalized Compounds. Chemistry - A European Journal, 2007, 13, 6082-6090.	1.7	65

#	ARTICLE	IF	CITATIONS
73	Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes. <i>Nuclear Medicine and Biology</i> , 2006, 33, 173-183.	0.3	46
74	[123I]Mtr-TOCA, a radioiodinated and carbohydrate analogue of octreotide: scintigraphic comparison with [111In]octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 45-52.	3.3	14
75	Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. <i>Journal of Nuclear Medicine</i> , 2006, 47, 566-73.	2.8	54
76	Modulation of Pharmacokinetics of Radioiodinated Sugar-Conjugated Somatostatin Analogues by Variation of Peptide Net Charge and Carbohydration Chemistry. <i>Bioconjugate Chemistry</i> , 2005, 16, 429-437.	1.8	37
77	N-Terminal Sugar Conjugation and C-Terminal Thr-for-Thr(ol) Exchange in Radioiodinated Tyr3-octreotide: A Effect on Cellular Ligand Trafficking in Vitro and Tumor Accumulation in Vivo. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2778-2789.	2.9	25
78	Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. <i>Radiochimica Acta</i> , 2004, 92, .	0.5	85
79	First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2004, 10, 3593-3606.	3.2	104
80	Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 231-244.	0.7	31
81	Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. <i>Journal of Nuclear Medicine</i> , 2004, 45, 892-902.	2.8	179
82	Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. <i>Tetrahedron Letters</i> , 2003, 44, 2393-2396.	0.7	28
83	Improvement of Pharmacokinetics of Radioiodinated Tyr3-Octreotide by Conjugation with Carbohydrates. <i>Bioconjugate Chemistry</i> , 2002, 13, 1021-1030.	1.8	90
84	Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydrate on the pharmacokinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 28-38.	3.3	51